-
Capricor announces that individuals with Duchenne treated with deramiocel had significantly less progression in loss of upper limb function
Capricor Therapeutics received early funding from CureDuchenne, and today Capricor released new data reporting that […]
-
Dyne announces new long-term data from DMD clinical trial skipping Exon 51
CureDuchenne provided early funding to Dyne Therapeutics, and is pleased to share that Dyne has […]
-
Individual with Duchenne dies from acute liver failure after gene therapy treatment
Sarepta Therapeutics has shared that a young man with Duchenne passed away following treatment with […]
-
MDA 2025: Deramiocel linked to sustained arm function preservation
Capricor Therapeutics’ investigational therapy deramiocel, formerly CAP-1002, which is being considered for approval in the […]
-
2025 MDA Clinical & Scientific Conference Updates
2025 MDA Conference Updates We’re at the 2025 MDA Clinical & Scientific Conference this week […]
-
A Safety Update on ELEVIDYS
We are deeply saddened by the loss of a young member of our community following […]
-
Making an Impact on Day 1 of the MDA Clinical and Scientific Conference
“This is a milestone year,” said Donald S. Wood, PhD, MDA’s President and CEO, as […]
-
MDA 2025: Conference begins, marking another year of progress
The Muscular Dystrophy Association‘s (MDA) annual Clinical & Scientific Conference kicked off over the weekend, […]
-
WATCH: Capricor Therapeutics – Update on Deramiocel for Cardiomyopathy in Patients with Duchenne (Webinar Recording)
Capricor Therapeutics recently joined PPMD for a community webinar to provide an update on their […]
-
Key Updates from the 2025 MDA Clinical & Scientific Conference
The 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference is underway in Dallas, Texas, […]
